# Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

> **NCT01571414** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 52 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** PA-824
- **DRUG:** Efavirenz (EFV)
- **DRUG:** Lopinavir/Ritonavir (LPV/r)
- **DRUG:** Rifampin (RIF)

## Key facts

- **NCT ID:** NCT01571414
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2021-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01571414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01571414, "Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01571414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*